SG11202103839UA - Substituted 6-azabenzimidazole compounds as hpk1 inhibitors - Google Patents

Substituted 6-azabenzimidazole compounds as hpk1 inhibitors

Info

Publication number
SG11202103839UA
SG11202103839UA SG11202103839UA SG11202103839UA SG11202103839UA SG 11202103839U A SG11202103839U A SG 11202103839UA SG 11202103839U A SG11202103839U A SG 11202103839UA SG 11202103839U A SG11202103839U A SG 11202103839UA SG 11202103839U A SG11202103839U A SG 11202103839UA
Authority
SG
Singapore
Prior art keywords
substituted
azabenzimidazole compounds
hpk1 inhibitors
hpk1
inhibitors
Prior art date
Application number
SG11202103839UA
Inventor
Gayatri Balan
Mark J Bartlett
Jayaraman Chandrasekhar
Julian A Codelli
John H Conway
Jennifer L Cosman
Rao V Kalla
Zachary A Kasun
Musong Kim
Seung H Lee
Jennifer R Lo
Jennifer A Loyer-Drew
Scott A Mitchell
Thao D Perry
Gary B Phillips
Patrick J Salvo
Sundaramoorthi Swaminathan
Veldhuizen Joshua J Van
Suet C Yeung
Jeff Zablocki
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of SG11202103839UA publication Critical patent/SG11202103839UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
SG11202103839UA 2018-10-31 2019-10-30 Substituted 6-azabenzimidazole compounds as hpk1 inhibitors SG11202103839UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862753339P 2018-10-31 2018-10-31
US201962868550P 2019-06-28 2019-06-28
PCT/US2019/058932 WO2020092621A1 (en) 2018-10-31 2019-10-30 Substituted 6-azabenzimidazole compounds as hpk1 inhibitors

Publications (1)

Publication Number Publication Date
SG11202103839UA true SG11202103839UA (en) 2021-05-28

Family

ID=68771764

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103839UA SG11202103839UA (en) 2018-10-31 2019-10-30 Substituted 6-azabenzimidazole compounds as hpk1 inhibitors

Country Status (24)

Country Link
US (2) US11203591B2 (en)
EP (2) EP4371987A1 (en)
JP (2) JP7460644B2 (en)
KR (1) KR102650496B1 (en)
AU (3) AU2019372046B2 (en)
BR (1) BR112021008255A2 (en)
CA (1) CA3117556A1 (en)
CL (1) CL2021001132A1 (en)
CO (1) CO2021005711A2 (en)
CR (1) CR20210215A (en)
DK (1) DK3873903T3 (en)
DO (2) DOP2021000079A (en)
FI (1) FI3873903T3 (en)
IL (1) IL282535B2 (en)
LT (1) LT3873903T (en)
MX (1) MX2021005047A (en)
PE (1) PE20211655A1 (en)
PH (1) PH12021551019A1 (en)
PL (1) PL3873903T3 (en)
PT (1) PT3873903T (en)
SG (1) SG11202103839UA (en)
TW (2) TWI721623B (en)
UA (1) UA126619C2 (en)
WO (1) WO2020092621A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6701088B2 (en) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders
EP3350183A1 (en) 2015-09-14 2018-07-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
JP7273172B2 (en) 2018-10-31 2023-05-12 ギリアード サイエンシーズ， インコーポレイテッド Substituted 6-azabenzimidazole compounds with HPK1 inhibitory activity
MX2021005047A (en) 2018-10-31 2021-09-08 Gilead Sciences Inc Substituted 6-azabenzimidazole compounds as hpk1 inhibitors.
BR112021014576A2 (en) 2019-01-25 2021-10-05 Brown University COMPOSITIONS AND METHODS FOR THE TREATMENT, PREVENTION OR REVERSAL OF INFLAMMATION AND AGE-ASSOCIATED DISORDERS
US11795223B2 (en) 2019-10-18 2023-10-24 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
AU2020374947A1 (en) 2019-10-31 2022-03-31 Forty Seven, Inc. Anti-CD47 and anti-CD20 based treatment of blood cancer
MX2022007930A (en) 2019-12-24 2022-08-08 Carna Biosciences Inc Diacylglycerol kinase modulating compounds.
PE20231067A1 (en) 2020-02-14 2023-07-17 Jounce Therapeutics Inc ANTIBODIES AND FUSION PROTEINS THAT BIND CCR8 AND THEIR USES
CN115605488A (en) 2020-05-06 2023-01-13 新锐思生物制药股份有限公司（Us） Bifunctional degradants of hematopoietic progenitor kinases and therapeutic uses thereof
TW202302145A (en) 2021-04-14 2023-01-16 美商基利科學股份有限公司 Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer
CN117460732A (en) * 2021-06-11 2024-01-26 杭州中美华东制药有限公司 Pyrrolopyridone compounds, preparation method and application thereof
US11926628B2 (en) 2021-06-23 2024-03-12 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240023628A (en) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 Diacylglycerol Kinase Modulating Compounds
IL309378A (en) 2021-06-23 2024-02-01 Gilead Sciences Inc Diacylglyercol kinase modulating compounds
CN117693503A (en) 2021-07-20 2024-03-12 阿斯利康(瑞典)有限公司 Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer
CN118139858A (en) 2021-10-28 2024-06-04 吉利德科学公司 Pyrazin-3 (2H) -one derivatives
AU2022376954A1 (en) 2021-10-29 2024-05-02 Gilead Sciences, Inc. Cd73 compounds
AU2022388571A1 (en) * 2021-11-10 2024-05-09 Gilead Sciences, Inc. Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
US20230220106A1 (en) 2021-12-08 2023-07-13 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
US20230203202A1 (en) 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
AU2022419982A1 (en) 2021-12-22 2024-06-06 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (en) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7 inhibitors
TW202346277A (en) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ikaros zinc finger family degraders and uses thereof
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (en) 2022-04-05 2023-12-01 美商基利科學股份有限公司 Combination therapy for treating colorectal cancer
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (513)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
CA2354591A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of jnk protein kinases
MXPA01009307A (en) 1999-03-17 2002-07-30 Astrazeneca Ab Amide derivatives.
JP2001302667A (en) 2000-04-28 2001-10-31 Bayer Ag Imidazopyrimidine derivative and triazolopyrimidine derivative
FR2828206B1 (en) 2001-08-03 2004-09-24 Centre Nat Rech Scient USE OF LYSYL OXIDASE INHIBITORS FOR CELL CULTURE AND TISSUE ENGINEERING
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
JP4879745B2 (en) 2003-10-03 2012-02-22 ポートラ ファーマシューティカルズ， インコーポレイテッド Substituted isoquinolinone
RU2006126791A (en) 2003-12-23 2008-01-27 Новартис АГ (CH) BICYCLIC HETEROCYCLIC INHIBITORS R-38 KINASES
LT2612862T (en) 2004-05-13 2017-01-25 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
JP2008504294A (en) 2004-06-25 2008-02-14 アムジエン・インコーポレーテツド Condensed triazoles and indazoles useful in the treatment of cytokine-mediated diseases and other diseases
PT2258376T (en) 2004-07-27 2019-05-31 Gilead Sciences Inc Phosphonate analogs of hiv inhibitor compounds
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
TW201402124A (en) 2005-08-19 2014-01-16 Array Biopharma Inc 8-substituted benzoazepines as toll-like receptor modulators
TWI382019B (en) 2005-08-19 2013-01-11 Array Biopharma Inc Aminodiazepines as toll-like receptor modulators
JPWO2007032371A1 (en) 2005-09-14 2009-03-19 大日本住友製薬株式会社 Oxindole derivatives as feeding regulators
US20070087988A1 (en) 2005-09-30 2007-04-19 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
TW200736260A (en) 2005-11-10 2007-10-01 Smithkline Beecham Corp Inhibitors of Akt activity
WO2008005555A1 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc. Modulators of toll-like receptor 7
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
WO2008046083A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
CA2672172C (en) 2006-12-22 2016-05-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
MY150746A (en) 2006-12-27 2014-02-28 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
MX2009006517A (en) 2006-12-27 2009-06-26 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives.
DE102007012645A1 (en) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituted imidazo and triazolopyrimidines
AU2008237507B2 (en) 2007-04-03 2014-03-20 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
DE102007019690A1 (en) 2007-04-26 2008-10-30 Bayer Healthcare Ag Use of cyclic substituted furopyrimidine derivatives for the treatment of pulmonary arterial hypertension
PT2170888E (en) 2007-06-29 2015-08-21 Gilead Sciences Inc Purine derivatives and their use as modulators of toll-like receptor 7
EP2019100A1 (en) 2007-07-19 2009-01-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
EP2020405A1 (en) 2007-07-30 2009-02-04 Santhera Pharmaceuticals (Schweiz) AG Substituted aryl or heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
SI2182981T1 (en) 2007-08-02 2013-05-31 Gilead Biologics, Inc. Methods and compositions for treatment and diagnosis of fibrosis
UA100250C2 (en) 2007-11-16 2012-12-10 Гілеад Сайнсіз, Інк. Inhibitors of human immunodeficiency virus replication
TWI434690B (en) 2007-12-19 2014-04-21 Dainippon Sumitomo Pharma Co Heterobicyclic derivatives
TW200938542A (en) 2008-02-01 2009-09-16 Irm Llc Compounds and compositions as kinase inhibitors
CN104042611B (en) 2008-07-08 2019-05-14 因塞特控股公司 1 of inhibitor as indoleamine 2,3-dioxygenase, 2,5- oxadiazoles
DK2313111T3 (en) 2008-08-01 2013-12-02 Ventirx Pharmaceuticals Inc Toll-like receptor agonist formulations and their use
WO2010019702A2 (en) 2008-08-12 2010-02-18 Oncomed Pharmaceuticals, Inc. Ddr1-binding agents and methods of use thereof
PT2331547E (en) 2008-08-22 2014-10-29 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
WO2010059393A1 (en) 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Serotonin receptor modulators
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
PT2364314E (en) 2008-12-09 2014-06-09 Gilead Sciences Inc Modulators of toll-like receptors
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
TWI625121B (en) 2009-07-13 2018-06-01 基利科學股份有限公司 Apoptosis signal-regulating kinase inhibitors
JP2013501002A (en) 2009-07-30 2013-01-10 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and compositions as SYK kinase inhibitors
AU2010284240B2 (en) 2009-08-18 2016-11-10 Array Biopharma, Inc. Substituted benzoazepines as Toll-like receptor modulators
AU2010284241B2 (en) 2009-08-18 2016-11-10 Array Biopharma, Inc. Substituted benzoazepines as Toll-like receptor modulators
AU2010310813B2 (en) 2009-10-22 2015-06-18 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
CN105622757A (en) 2010-02-04 2016-06-01 吉联亚生物科技有限公司 Antibodies that bind to lysyl oxidase-like 2(LOXL2) and methods of use therefor
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
WO2011119777A2 (en) 2010-03-23 2011-09-29 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
WO2011130146A1 (en) 2010-04-14 2011-10-20 Array Biopharma Inc. 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
SG185617A1 (en) 2010-05-31 2012-12-28 Ono Pharmaceutical Co Purinone derivative
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EA201291301A1 (en) 2010-07-02 2013-05-30 Джилид Сайэнс, Инк. Derivatives of 2-quinoline acid moiety as anti-viral compounds against HIV
PE20130385A1 (en) 2010-07-02 2013-03-30 Gilead Sciences Inc DERIVATIVES OF NAFT-2-ILACETIC ACID TO TREAT AIDS
TW201211028A (en) 2010-08-10 2012-03-16 Dainippon Sumitomo Pharma Co Fused ring pyrrolidine derivatives
PE20131376A1 (en) 2010-08-27 2013-11-25 Gilead Biologics Inc ANTIBODIES TO MATRIX METALOPROTEINASE-9
CN103237549A (en) 2010-10-01 2013-08-07 帆德制药股份有限公司 Methods for treatment of allergic diseases
SG189071A1 (en) 2010-10-01 2013-05-31 Ventirx Pharmaceuticals Inc Therapeutic use of a tlr agonist and combination therapy
CN107699585A (en) 2010-12-09 2018-02-16 宾夕法尼亚大学董事会 The purposes of the T cell treating cancer of Chimeric antigen receptor modification
UY33775A (en) 2010-12-10 2012-07-31 Gilead Sciences Inc MACROCYCLIC INHIBITORS OF VIRUS FLAVIVIRIDAE, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND THEIR USES
EP2663550B1 (en) 2011-01-12 2016-12-14 VentiRx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
WO2012097177A2 (en) 2011-01-12 2012-07-19 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
WO2012097479A1 (en) 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic inhibitors of anaphastic lymphoma kinase
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
PE20140844A1 (en) 2011-02-12 2014-07-14 Globeimmune Inc YEAST-BASED THERAPEUTICS FOR CHRONIC HEPATITIS B INFECTION
US20140005188A1 (en) 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
EP3590928B1 (en) 2011-04-08 2021-06-09 Janssen Sciences Ireland Unlimited Company Pyrimidine derivatives for the treatment of viral infections
WO2012145728A1 (en) 2011-04-21 2012-10-26 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
NO2709989T3 (en) 2011-05-18 2018-05-19
EP2717895A1 (en) 2011-06-08 2014-04-16 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (en) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 Antiviral compound
DE102011080362A1 (en) 2011-08-03 2013-02-07 Robert Bosch Gmbh Electrical contact element with locking lance for a connector housing
BR112014002675A2 (en) 2011-08-04 2017-02-21 Array Biopharma Inc "Quinazoline as serine / threonine kinase inhibitors, their uses, and composition"
JP6101205B2 (en) 2011-08-23 2017-03-22 中外製薬株式会社 Novel anti-DDR1 antibody having antitumor activity
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
WO2013052699A2 (en) 2011-10-04 2013-04-11 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
AU2012323399A1 (en) 2011-10-12 2014-05-29 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
LT2786996T (en) 2011-11-29 2017-01-10 Ono Pharmaceutical Co., Ltd. Purinone derivative hydrochloride
JP6144698B2 (en) 2011-12-20 2017-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Fused tricyclic compounds as inhibitors of HIV replication
EA037918B1 (en) 2011-12-21 2021-06-07 Новира Терапьютикс, Инк. Hepatitis b antiviral agents
UY34573A (en) 2012-01-27 2013-06-28 Gilead Sciences Inc QUINASE INHIBITOR REGULATING THE APOPTOSIS SIGNAL
WO2013110198A1 (en) * 2012-01-27 2013-08-01 Université de Montréal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
EP2812331B1 (en) 2012-02-08 2019-01-02 Janssen Sciences Ireland Unlimited Company Piperidino-pyrimidine derivatives for the treatment of viral infections
JP6138831B2 (en) 2012-02-09 2017-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Furo [3,2-b]-and thieno [3,2-b] pyridine derivatives as TBK1 and IKK inhibitors
US9394297B2 (en) 2012-02-28 2016-07-19 Amgen Inc. Amides as pim inhibitors
EP2822957A1 (en) 2012-03-07 2015-01-14 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
KR20140142736A (en) 2012-03-29 2014-12-12 오리진 디스커버리 테크놀로지스 리미티드 Immunomodulating cyclic compounds from the bc loop of human pd1
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
KR20140143160A (en) 2012-03-31 2014-12-15 에프. 호프만-라 로슈 아게 Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EP2788336B1 (en) 2012-04-20 2016-03-02 Gilead Sciences, Inc. Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
PL2859009T3 (en) 2012-06-08 2018-03-30 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
AR091279A1 (en) 2012-06-08 2015-01-21 Gilead Sciences Inc MACROCICLIC INHIBITORS OF VIRUS FLAVIVIRIDAE
CA2875692A1 (en) 2012-06-08 2013-12-12 Selcia Limited Macrocyclic inhibitors of flaviviridae viruses
MY183534A (en) 2012-08-10 2021-02-25 Janssen Sciences Ireland Uc Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
CR20200276A (en) 2012-08-28 2021-01-27 Janssen Sciences Ireland Uc SULFAMOYLARYLAMIDES AND THEIR USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B (DIVISIONAL EXP. 2015-0059)
DK2890683T3 (en) 2012-08-28 2017-01-30 Janssen Sciences Ireland Uc MERGED BICYCLIC SULFAMOYL DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
PE20150776A1 (en) 2012-09-10 2015-05-21 Hoffmann La Roche 6-AMINO ACID-HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
WO2014047624A1 (en) 2012-09-24 2014-03-27 Gilead Sciences, Inc. Anti-ddr1 antibodies
PL2903968T3 (en) 2012-10-02 2017-05-31 Gilead Sciences, Inc. Inhibitors of histone demethylases
CA2884478C (en) 2012-10-10 2021-02-16 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
KR101268466B1 (en) 2012-11-12 2013-06-04 유병수 Slanted windmill
AU2013346793B2 (en) 2012-11-16 2018-03-08 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
WO2014089364A1 (en) 2012-12-06 2014-06-12 Quanticel Pharmaceuticals, Inc Histone demethylase inhibitors
PT2934145T (en) 2012-12-19 2018-02-13 Celgene Quanticel Res Inc Histone demethylase inhibitors
AU2013361694B2 (en) 2012-12-20 2017-10-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
SG11201504857SA (en) 2012-12-21 2015-07-30 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NZ708870A (en) 2012-12-21 2016-09-30 Gilead Calistoga Llc Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
CA2895782C (en) 2012-12-21 2017-08-22 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
WO2014100818A1 (en) 2012-12-21 2014-06-26 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US20140221380A1 (en) 2012-12-27 2014-08-07 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
CN103114087B (en) 2013-01-24 2015-05-06 北京大学第三医院 RNA(Ribonucleic Acid)and application thereof in diseases of cardiovascular system
CN103110932B (en) 2013-01-24 2015-08-19 北京大学第三医院 The novelty teabag of a kind of HIP-55
JP6404835B2 (en) 2013-02-21 2018-10-17 ヤンセン・サイエンシズ・アイルランド・ユーシー 2-Aminopyrimidine derivatives for the treatment of viral infections
CN105263906B (en) 2013-02-27 2018-11-23 吉利德科学公司 The inhibitor of histone demethylase
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
JP6320506B2 (en) 2013-03-12 2018-05-09 セルジーン クオンティセル リサーチ，インク． Histone demethylase inhibitor
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
US9187454B2 (en) 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
EP2970307B1 (en) 2013-03-13 2020-03-11 Genentech, Inc. Pyrazolo compounds and uses thereof
ES2731773T3 (en) 2013-03-14 2019-11-19 Celgene Quanticel Res Inc Histone Demethylase Inhibitors
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
PL2970211T3 (en) 2013-03-15 2018-01-31 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US20140329889A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
JP6533217B2 (en) 2013-05-17 2019-06-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 6-Bridged Heteroaryldihydropyrimidines for the Treatment and Prevention of Hepatitis B Virus Infection
CN105960400B (en) 2013-05-17 2019-05-31 爱尔兰詹森科学公司 Sulfamoylthiophene amide derivatives and its purposes for being used to treat hepatitis B as drug
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JP6030783B2 (en) 2013-06-14 2016-11-24 ギリアード サイエンシーズ， インコーポレイテッド Phosphatidylinositol 3-kinase inhibitor
MX370661B (en) 2013-06-19 2019-12-19 Hoffmann La Roche Indolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives.
WO2015011281A1 (en) 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
EP3404031B1 (en) 2013-07-30 2020-09-23 Janssen Sciences Ireland Unlimited Company Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
EA031601B1 (en) 2013-07-31 2019-01-31 Джилид Сайэнс, Инк. Syk INHIBITORS
WO2015019284A2 (en) 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
WO2015023958A1 (en) 2013-08-15 2015-02-19 The University Of Kansas Toll-like receptor agonists
ES2642074T3 (en) 2013-09-04 2017-11-15 Bristol-Myers Squibb Company Useful compounds as immunomodulators
SG11201601682RA (en) 2013-09-06 2016-04-28 Aurigene Discovery Tech Ltd 1,2,4-oxadiazole derivatives as immunomodulators
ES2683356T3 (en) 2013-09-06 2018-09-26 Aurigene Discovery Technologies Limited Cyclic peptidomimetic compounds as immunomodulators
KR20160081898A (en) 2013-09-06 2016-07-08 오리진 디스커버리 테크놀로지스 리미티드 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
AU2014320463B2 (en) 2013-09-11 2018-08-02 Centre National De La Recherche Scientifique (Cnrs) Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
TWI702218B (en) 2013-10-14 2020-08-21 日商衛材R&D企管股份有限公司 Selectively substituted quinoline compounds
CN107935988A (en) 2013-10-14 2018-04-20 卫材R&D管理有限公司 The quinoline compound selectively substituted
UA117261C2 (en) 2013-10-23 2018-07-10 ЯНССЕН САЙЄНСЕЗ АЙРЛЕНД ЮСі Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
AU2014348518B2 (en) 2013-11-14 2019-01-03 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
WO2015082887A2 (en) 2013-12-02 2015-06-11 Bergenbio As Use of kinase inhibitors
JP2016540013A (en) 2013-12-13 2016-12-22 武田薬品工業株式会社 Pyrrolo [3,2-C] pyridine derivatives as TLR inhibitors
CA2932353A1 (en) 2013-12-13 2015-06-18 Steven P. Treon Methods to treat lymphoplasmacytic lymphoma
WO2015089479A1 (en) 2013-12-13 2015-06-18 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US10654807B2 (en) 2013-12-20 2020-05-19 The University Of Kansas Toll-like receptor 8 agonists
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
CA2931329A1 (en) 2014-01-30 2015-08-06 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
SG11201606428UA (en) 2014-02-04 2016-09-29 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
AU2015214961B2 (en) 2014-02-06 2018-08-30 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
KR20220127940A (en) 2014-03-05 2022-09-20 브리스톨-마이어스 스큅 컴퍼니 Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
RS58384B1 (en) 2014-03-07 2019-04-30 Hoffmann La Roche Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
LT3119772T (en) 2014-03-19 2019-08-26 Boehringer Ingelheim International Gmbh Heteroaryl syk inhibitors
PE20170331A1 (en) 2014-03-24 2017-04-28 Guangdong Zhongsheng Pharmaceutical Co Ltd QUINOLINE DERIVATIVES AS SMO INHIBITORS
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
JP6765968B2 (en) 2014-04-10 2020-10-07 シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート Expression of transgene by drug control
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
BR112016017261B1 (en) 2014-04-22 2022-04-19 F. Hoffmann-La Roche Ag Compound, pharmaceutical composition, use of a compound and process for making a compound
WO2015168269A1 (en) 2014-05-01 2015-11-05 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
CA2945504A1 (en) 2014-05-01 2015-11-05 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
CN106459032B (en) 2014-05-13 2019-04-05 豪夫迈·罗氏有限公司 Treat and prevent hepatitis b virus infected new dihydro Quinolizinone type
MX2016015363A (en) 2014-05-23 2017-05-30 Eisai R&D Man Co Ltd Combination therapies for the treatment of cancer.
WO2015188085A1 (en) 2014-06-06 2015-12-10 Flexus Biosciences, Inc. Immunoregulatory agents
US9580416B2 (en) 2014-07-02 2017-02-28 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
EP3174538B1 (en) 2014-08-01 2019-11-06 3M Innovative Properties Company Methods and therapeutic combinations for treating tumors
CA2952541C (en) 2014-08-14 2019-10-01 F. Hoffmann-La Roche Ag Pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection
CN110938076B (en) 2014-08-15 2021-08-10 正大天晴药业集团股份有限公司 Pyrrolopyrimidines as TLR7 agonists
CN107108629A (en) 2014-08-22 2017-08-29 贾纳斯生物治疗有限公司 Novel N2, N4, N7, the 6 quaternary triamines of pteridine 2,4,7 and 2,4,6,7 quaternary pteridine compounds and its synthesis and application method
MA40470A (en) 2014-08-27 2016-03-03 Gilead Sciences Inc Compounds and methods for inhibiting histone demethylases
TWI751102B (en) 2014-08-28 2022-01-01 美商奇諾治療有限公司 Antibodies and chimeric antigen receptors specific for cd19
US9884866B2 (en) 2014-09-08 2018-02-06 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
CN106999536B (en) 2014-09-11 2020-11-27 百时美施贵宝公司 Macrocyclic inhibitors of PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
WO2016049276A1 (en) 2014-09-25 2016-03-31 Moffitt Genetics Corporation Prognostic tumor biomarkers
EP3204379B1 (en) 2014-10-10 2019-03-06 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
EP3204392A1 (en) 2014-10-11 2017-08-16 F. Hoffmann-La Roche AG Compounds for use in the treatment of infectious diseases
KR102548547B1 (en) 2014-10-31 2023-06-27 제노사이언스 파마 Substituted 2,4 diamino-quinoline as new anticancer agents
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
WO2016073378A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Assays for detecting t cell immune subsets and methods of use thereof
JP2017538678A (en) 2014-11-05 2017-12-28 フレクサス・バイオサイエンシーズ・インコーポレイテッドＦｌｅｘｕｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． Immunomodulator
UY36390A (en) 2014-11-05 2016-06-01 Flexus Biosciences Inc MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BE1023340B1 (en) 2014-11-13 2017-02-08 Glaxosmithkline Biologicals S.A. COMPOUNDS
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
MX2017007138A (en) 2014-12-03 2017-08-28 Juno Therapeutics Inc Methods and compositions for adoptive cell therapy.
JP2017537929A (en) 2014-12-05 2017-12-21 ジェネンテック， インコーポレイテッド Methods and compositions for cancer treatment using PD-1 axis antagonists and HPK1 antagonists
PL3230298T3 (en) 2014-12-08 2021-06-14 F.Hoffmann-La Roche Ag 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
JP6821568B2 (en) 2014-12-15 2021-01-27 ベリカム ファーマシューティカルズ， インコーポレイテッド Controlled elimination method of therapeutic cells
WO2016097870A1 (en) 2014-12-17 2016-06-23 Zenith Epigenetics Corp. Substituted bicyclic compounds as bromodomain inhibitors
WO2016097863A1 (en) 2014-12-17 2016-06-23 Zenith Epigenetics Corp. Inhibitors of bromodomains
EP3233835B1 (en) 2014-12-18 2019-01-23 F.Hoffmann-La Roche Ag Benzazepine sulfonamide compounds
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
WO2016102438A1 (en) 2014-12-23 2016-06-30 F. Hoffmann-La Roche Ag Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine analogues
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
PL410665A1 (en) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Arginase inhibitors and their therapeutical applications
CN105732635A (en) 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 Toll-like receptor 7 agonist
CA2972434A1 (en) 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis b infections
WO2016107832A1 (en) 2014-12-30 2016-07-07 F. Hoffmann-La Roche Ag Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
MA41291A (en) 2014-12-30 2017-11-07 Forma Therapeutics Inc PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER
WO2016106652A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Biarylether imidazopyrazine btk inhibitors
WO2016107833A1 (en) 2014-12-31 2016-07-07 F. Hoffmann-La Roche Ag A novel high-throughput method for quantification of hbv cccdna from cell lysate by real-time pcr
WO2016106623A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
WO2016106625A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106626A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
WO2016106624A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
EP3042903B1 (en) 2015-01-06 2019-08-14 Impetis Biosciences Ltd. Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
MA41338B1 (en) 2015-01-16 2019-07-31 Hoffmann La Roche Pyrazine compounds for the treatment of infectious diseases
WO2016120186A1 (en) 2015-01-27 2016-08-04 F. Hoffmann-La Roche Ag Recombinant hbv cccdna, the method to generate thereof and the use thereof
CN107406417B (en) 2015-01-28 2020-06-09 拜耳制药股份公司 4H-pyrrolo [3,2-c ] pyridin-4-one derivatives
WO2016126460A2 (en) 2015-02-06 2016-08-11 Proteq Technologies Llc Electrochromic devices
JP6435054B2 (en) 2015-02-11 2018-12-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Novel 2-oxo-6,7-dihydrobenzo [a] quinolidine-3-carboxylic acid derivatives for the treatment and prevention of hepatitis B virus infection
CN104878084B (en) 2015-03-04 2018-01-09 上海市杨浦区中心医院 Detect kit of the oxaliplatin for colorectal cancer validity
UA123090C2 (en) 2015-03-04 2021-02-17 Гіліад Сайєнсіз, Інк. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
SI3265458T1 (en) 2015-03-06 2019-03-29 F. Hoffmann-La Roche Ag Benzazepine dicarboxamide compounds
CN107427491A (en) 2015-03-10 2017-12-01 奥瑞基尼探索技术有限公司 Therapeutic cyclic compound as immunomodulator
WO2016145252A1 (en) 2015-03-10 2016-09-15 The Trustees Of Princeton University Shmt inhibitors
MX2017011614A (en) 2015-03-10 2018-03-23 Aurigene Discovery Tech Ltd 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators.
JP2018507894A (en) 2015-03-10 2018-03-22 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 3-Substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
CN107427497A (en) 2015-03-10 2017-12-01 奥瑞基尼探索技术有限公司 1,3,4 oxadiazoles and thiadiazole compound as 3 substitutions of immunomodulator
HUE058274T2 (en) 2015-03-10 2022-07-28 Aurigene Discovery Tech Ltd 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
GB201504314D0 (en) 2015-03-13 2015-04-29 Univ Dundee Small molecules
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
JP7269731B2 (en) 2015-03-18 2023-05-09 アルビナス・オペレーションズ・インコーポレイテッド Compounds and methods for enhancing target protein degradation
US10710978B2 (en) 2015-03-31 2020-07-14 Dana-Farber Cancer Institute, Inc. STK4 inhibitors for treatment of hematologic malignancies
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
WO2016161196A1 (en) 2015-04-03 2016-10-06 Mirna Therapeutics, Inc. Microrna-34 immunotherapy
WO2016164428A1 (en) 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2016162867A1 (en) 2015-04-08 2016-10-13 Efranat Ltd. Combination therapy of macrophage activating factor and pd-1 signaling inhibitors
KR20170137165A (en) 2015-04-10 2017-12-12 베이진 엘티디 A novel 5 or 8-substituted imidazo [1,5-a] pyridine as indole amine and / or tryptophan 2,3-dioxygenase
WO2016168619A1 (en) 2015-04-17 2016-10-20 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
AU2016252038B2 (en) 2015-04-20 2021-08-12 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
WO2016176726A1 (en) 2015-05-01 2016-11-10 Griffith University Diagnostic methods
EP3292120B1 (en) 2015-05-04 2019-06-19 H. Hoffnabb-La Roche Ag Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
WO2016180743A1 (en) 2015-05-12 2016-11-17 F. Hoffmann-La Roche Ag Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
EP3303586A1 (en) 2015-05-29 2018-04-11 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
US10196701B2 (en) 2015-06-01 2019-02-05 The Penn State Research Foundation Hepatitis B virus capsid assembly
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
PL3322711T3 (en) 2015-06-25 2021-10-25 University Health Network Hpk1 inhibitors and methods of using same
US20160376864A1 (en) 2015-06-29 2016-12-29 Cameron International Corporation Apparatus and method for distributing fluids to a wellbore
CN107820498B (en) 2015-06-30 2020-06-19 豪夫迈·罗氏有限公司 Substituted aminothiazolopyrimidinediones for the treatment and prevention of viral infections
GB201511477D0 (en) 2015-06-30 2015-08-12 Redx Pharma Plc Antiviral compounds
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CA2990335A1 (en) 2015-07-02 2017-01-05 Glaxosmithkline Intellectual Property Development Limited Inhibitors of indoleamine 2,3-dioxygenase
WO2017007701A1 (en) 2015-07-07 2017-01-12 Merck Sharp & Dohme Corp. Antiviral phosphodiamide compounds
EP3325477B1 (en) 2015-07-21 2019-05-01 H. Hoffnabb-La Roche Ag Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2017016960A1 (en) 2015-07-24 2017-02-02 F. Hoffmann-La Roche Ag Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
WO2017017042A1 (en) 2015-07-27 2017-02-02 F. Hoffmann-La Roche Ag Novel tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
JP6559324B2 (en) 2015-07-28 2019-08-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Novel 6,7-dihydropyrido [2,1-a] phthalazin-2-ones for the treatment and prevention of hepatitis B virus infection
CA2993908A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination of pd-1 antagonist with an egfr inhibitor
EP3332027A1 (en) 2015-08-06 2018-06-13 Stichting Katholieke Universiteit Method for the prediction of progression of bladder cancer
CN107849071B (en) 2015-08-10 2021-03-09 默沙东公司 Antiviral beta amino acid ester phosphorodiamidate compounds
WO2017027645A1 (en) 2015-08-13 2017-02-16 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
US11130736B2 (en) 2015-08-21 2021-09-28 University Of Kansas Human TLR8-selective agonists
WO2017038909A1 (en) 2015-08-28 2017-03-09 Takeda Pharmaceutical Company Limited Heterocyclic compounds
CN108026092B (en) 2015-08-31 2021-01-26 3M创新有限公司 Guanidine-substituted imidazo [4,5-c ] ring compounds
TW201720802A (en) 2015-09-15 2017-06-16 艾森伯利生物科學公司 Hepatitis B core protein modulators
EP3350168B1 (en) 2015-09-17 2019-12-18 H. Hoffnabb-La Roche Ag Sulfinylphenyl or sulfonimidoylphenyl benzazepines
SG10202110257UA (en) 2015-09-17 2021-10-28 Novartis Ag Car t cell therapies with enhanced efficacy
JP6856900B2 (en) 2015-09-17 2021-04-14 国立大学法人富山大学 Toll-like receptor 7 or toll-like receptor 9 activation inhibitor
FR3041639B1 (en) 2015-09-30 2019-01-25 Les Laboratoires Servier NOVEL IMIDAZO [4,5-b] PYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR3041640B1 (en) 2015-09-30 2019-05-17 Les Laboratoires Servier NOVEL PYRROLO [2,3-d] PYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2017061466A1 (en) 2015-10-05 2017-04-13 富山化学工業株式会社 Anti-hepatitis b virus agent
EP3360864B1 (en) 2015-10-07 2021-04-28 Sumitomo Dainippon Pharma Co., Ltd. Pyrimidine compound
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
TW201718581A (en) 2015-10-19 2017-06-01 英塞特公司 Heterocyclic compounds as immunomodulators
WO2017075477A1 (en) 2015-10-28 2017-05-04 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
WO2017079669A1 (en) 2015-11-04 2017-05-11 Incyte Corporation Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
AU2016349080B2 (en) 2015-11-05 2019-03-14 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 7-(thiazol-5-yl) pyrrolopyrimidine compound as TLR7 agonist
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
US11213586B2 (en) 2015-11-19 2022-01-04 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)
EP3377523A4 (en) 2015-11-19 2019-06-19 The Regents of The University of California Conditionally repressible immune cell receptors and methods of use thereof
CA3006930A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
EP3386512B1 (en) 2015-12-10 2023-11-22 Merck Sharp & Dohme LLC Antiviral phosphodiamide prodrugs of tenofovir
WO2017106740A1 (en) 2015-12-16 2017-06-22 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
ITUB20159605A1 (en) 2015-12-17 2017-06-17 Alda S R L KINASE AND UBIQUITIN LIGASE INHIBITORS AND USES THEREOF
EP3390361B1 (en) 2015-12-17 2022-03-16 Incyte Corporation N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
CA3005766A1 (en) 2015-12-17 2017-06-22 Merck Patent Gmbh Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
UA126113C2 (en) 2015-12-22 2022-08-17 Інсайт Корпорейшн Heterocyclic compounds as immunomodulators
CA3004491A1 (en) 2016-01-08 2017-07-13 The Regents Of The University Of California Conditionally active heterodimeric polypeptides and methods of use thereof
AU2017219216B2 (en) 2016-02-19 2019-12-19 Novartis Ag Tetracyclic pyridone compounds as antivirals
WO2017151732A1 (en) 2016-03-02 2017-09-08 Beth Israel Deaconess Medical Center Technology Venture Office, Br2 Therapeutic targets for lin-28-expressing cancers
WO2017156454A1 (en) 2016-03-10 2017-09-14 The Regents Of The University Of California Anti-cancer and splce modulating compounds and methods
PL3429596T3 (en) 2016-03-18 2022-12-19 Immune Sensor, Llc Cyclic di-nucleotide compounds and methods of use
AU2017238758B2 (en) 2016-03-21 2021-01-21 Council Of Scientific & Industrial Research Blocking toll-like receptor 9 signaling with small molecule antagonist
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
TWI751155B (en) 2016-04-15 2022-01-01 美商雅酶股份有限公司 Amine-substituted aryl or heteroaryl compounds
JP7104633B6 (en) 2016-04-19 2023-12-22 イネイト・テューマー・イミュニティ・インコーポレイテッド NLRP3 modifier
WO2017184735A1 (en) 2016-04-19 2017-10-26 Ifm Therapeutics, Inc Nlrp3 modulators
EP3448393A1 (en) 2016-04-25 2019-03-06 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
AR108396A1 (en) 2016-05-06 2018-08-15 Incyte Corp HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
ES2907981T3 (en) 2016-05-06 2022-04-27 Shanghai De Novo Pharmatech Co Ltd Benzazepine derivative, preparation method, pharmaceutical composition and use thereof
JP6957518B2 (en) 2016-05-20 2021-11-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ A novel pyrazine compound with oxygen, sulfur and nitrogen linkers for the treatment of infectious diseases
EP3464274B1 (en) 2016-05-23 2020-05-27 H. Hoffnabb-La Roche Ag Benzazepine dicarboxamide compounds with secondary amide function
WO2017202704A1 (en) 2016-05-23 2017-11-30 F. Hoffmann-La Roche Ag Benzazepine dicarboxamide compounds with tertiary amide function
ES2905980T3 (en) 2016-05-26 2022-04-12 Incyte Corp Heterocyclic compounds as immunomodulators
EP3464278B1 (en) 2016-05-26 2021-06-16 F. Hoffmann-La Roche AG Xanthone derivatives for the treatment and prophylaxis of hepatitis b virus disease
WO2017211791A1 (en) 2016-06-07 2017-12-14 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and a tlr7 agonist
BR112018075465A2 (en) 2016-06-10 2019-03-19 Enanta Pharmaceuticals, Inc. hepatitis b antiviral agents
EP3468963B1 (en) 2016-06-12 2021-10-27 F. Hoffmann-La Roche AG Dihydropyrimidinyl benzazepine carboxamide compounds
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
CA3028685A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Heterocyclic compounds as immunomodulators
CN109641893B (en) 2016-06-20 2021-07-20 大邱庆北尖端医疗产业振兴财团 Novel imidazopyridine derivatives, process for their preparation and their use
CN108290893B (en) 2016-06-22 2021-01-05 四川科伦博泰生物医药股份有限公司 Dihydroperidinone derivatives, preparation method and application thereof
KR101789430B1 (en) 2016-06-28 2017-10-25 동국대학교 산학협력단 Novel compound having SMO-inhibitory activity and composition for preventing or treating cancer comprising the same as an active ingredient
WO2018001944A1 (en) 2016-06-29 2018-01-04 F. Hoffmann-La Roche Ag Novel dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
EP3478683B1 (en) 2016-06-29 2021-07-21 Novira Therapeutics Inc. Diazepinone derivatives and their use in the treatment of hepatitis b infections
EP3478680B1 (en) 2016-06-29 2020-04-22 H. Hoffnabb-La Roche Ag Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hbv infection
CA3029688A1 (en) 2016-06-29 2018-01-04 Novira Therapeutics, Inc. Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections
KR102468272B1 (en) 2016-06-30 2022-11-18 삼성전자주식회사 Acoustic output device and control method thereof
JP7171444B2 (en) 2016-07-01 2022-11-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Dihydropyranopyrimidines for treating viral infections
JP6301402B2 (en) 2016-07-01 2018-03-28 日新製鋼株式会社 Ferritic stainless steel sheet and manufacturing method thereof
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CA3029991A1 (en) 2016-07-08 2018-01-11 Bristol-Myers Squibb Company 1,3-dihydroxy-phenyl derivatives useful as immunomodulators
WO2018011162A1 (en) 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag Carboxy 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
WO2018011160A1 (en) 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
WO2018011163A1 (en) 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
JP6936848B2 (en) 2016-07-14 2021-09-22 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ A novel tetrahydropyrazolopyridine compound for the treatment of infectious diseases
WO2018019297A1 (en) 2016-07-29 2018-02-01 银杏树药业(苏州)有限公司 Isoquinolinone compound and use thereof in preparation of antiviral drugs
WO2018022282A1 (en) 2016-07-29 2018-02-01 Newave Pharmaceutical Inc. Novel therapeutic agents for the treatment of hbv infection
SG11201900619XA (en) 2016-07-30 2019-02-27 Bristol Myers Squibb Co Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
EP3493804A1 (en) 2016-08-03 2019-06-12 Arising International, Inc. Symmetric or semi-symmetric compounds useful as immunomodulators
EP3503894A1 (en) 2016-08-24 2019-07-03 H. Hoffnabb-La Roche Ag Combination therapy of an hbv capsid assembly inhibitor and a nucleos(t)ide analogue
CN109641920A (en) 2016-08-26 2019-04-16 3M创新有限公司 Condensed [1,2] imidazo [4,5-c] cycle compound replaced by guanidino group
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
EP3507276B1 (en) 2016-09-02 2021-11-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
WO2018043747A1 (en) 2016-09-05 2018-03-08 国立大学法人京都大学 Anti-hepatitis b virus agent
EP3510036B1 (en) 2016-09-07 2021-07-21 GlaxoSmithKline Biologicals SA Imidazoquinoline derivatives and their use in therapy
RS62913B1 (en) 2016-09-09 2022-03-31 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
KR102519535B1 (en) 2016-09-09 2023-04-06 브리스톨-마이어스 스큅 컴퍼니 Pyridyl substituted indole compounds
WO2018049152A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
TWI670266B (en) 2016-09-09 2019-09-01 大陸商浙江海正藥業股份有限公司 Dihydropyrimidine compounds, processes for their preparation and use thereof
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
ES2927104T3 (en) * 2016-09-09 2022-11-02 Incyte Corp Pyrazolopyridine derivatives as modulators of HPK1 and uses thereof for the treatment of cancer
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018051255A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2018051254A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
RS62410B1 (en) 2016-10-04 2021-10-29 Merck Sharp & Dohme Benzo[b]thiophene compounds as sting agonists
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
WO2018065360A1 (en) 2016-10-07 2018-04-12 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways
JP7189870B2 (en) 2016-10-20 2022-12-14 アウリジーン ディスカバリー テクノロジーズ リミテッド Dual inhibitor of VISTA and PD-1 pathways
US10736908B2 (en) 2016-10-26 2020-08-11 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
WO2018081531A2 (en) 2016-10-28 2018-05-03 Ariad Pharmaceuticals, Inc. Methods for human t-cell activation
WO2018078149A1 (en) 2016-10-31 2018-05-03 F. Hoffmann-La Roche Ag Novel cyclicsulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
US10988507B2 (en) 2016-11-07 2021-04-27 Bristol-Myers Squibb Company Immunomodulators
US11370794B2 (en) 2016-11-11 2022-06-28 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use
CN109937040A (en) 2016-11-11 2019-06-25 吉利德科学公司 The method for treating hepatopathy
EP3539963A4 (en) 2016-11-11 2020-05-13 Hepo Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use
JOP20170188A1 (en) 2016-11-25 2019-01-30 Janssen Biotech Inc Cyclic dinucleotides as sting agonists
WO2018095426A1 (en) 2016-11-28 2018-05-31 江苏恒瑞医药股份有限公司 Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
US11180482B2 (en) 2016-11-30 2021-11-23 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
JOP20170192A1 (en) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co Cyclic dinucleotide
AU2017378782A1 (en) 2016-12-20 2019-07-04 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
CA3047113A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment
JP7106572B2 (en) 2016-12-20 2022-07-26 ブリストル－マイヤーズ スクイブ カンパニー Compounds Useful as Immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
AU2017382870B2 (en) 2016-12-22 2022-03-24 Incyte Corporation Benzooxazole derivatives as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
TW201829412A (en) 2016-12-22 2018-08-16 美商默沙東藥廠 Antiviral aliphatic ester prodrugs of tenofovir
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
CN110035760A (en) 2016-12-22 2019-07-19 默沙东公司 Antiviral benzyl amine phosphordiamidite compounds
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
US20180228786A1 (en) * 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
CN110402248B (en) 2017-03-15 2023-01-06 豪夫迈·罗氏有限公司 Azaindoles as HPK1 inhibitors
EP4122464B1 (en) 2017-03-28 2024-05-15 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
MA48994A (en) 2017-03-30 2020-02-05 Hoffmann La Roche ISOQUINOLEINS USED AS HPK1 INHIBITORS
JP7154221B2 (en) 2017-03-30 2022-10-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Naphthyridine as an inhibitor of HPK1
JP2021506735A (en) 2017-05-26 2021-02-22 イクノス サイエンシズ エスエー New MAP4K1 inhibitor
EP3638671A1 (en) 2017-06-13 2020-04-22 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
WO2018228920A1 (en) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
CA3079060A1 (en) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
WO2019027987A2 (en) 2017-07-31 2019-02-07 The Johns Hopkins University Compositions and methods for targeting masas to treat cancers with spliceosome mutations
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
CN109517820B (en) 2017-09-20 2021-09-24 北京宇繁生物科技有限公司 gRNA of target HPK1 and HPK1 gene editing method
CN109721620B (en) 2017-10-27 2022-05-13 药捷安康(南京)科技股份有限公司 HPK1 inhibitors and uses thereof
JP2021505526A (en) 2017-10-31 2021-02-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 Combinations comprising at least one spliceosome modulator and at least one inhibitor selected from BCL2 inhibitors, BCL2 / BCLXL inhibitors and BCLXL inhibitors, and methods of use.
WO2019090198A1 (en) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
EP3842433B1 (en) 2018-01-19 2023-11-01 Medshine Discovery Inc. Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
SI3755703T1 (en) 2018-02-20 2022-11-30 Incyte Corporation N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
WO2019200120A1 (en) 2018-04-11 2019-10-17 Lycera Corporation Dihydroisoquinoline-2(1h)-carboxamide and related compounds and their use in treating medical conditions
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
WO2019206049A1 (en) 2018-04-25 2019-10-31 Zhuhai Yufan Biotechnologies Co., Ltd Hpk1 inhibitors, preparation method and application thereof
CN108823307B (en) 2018-05-17 2020-10-30 浙江大学 Application of PD-L1 spliceosome B as marker for guiding medication of anti-PD-L1/PD 1 immunotherapy
WO2019238067A1 (en) 2018-06-13 2019-12-19 Beigene, Ltd. Pyrrolo [2, 3-b] pyridines or pyrrolo [2, 3-b] pyrazines as hpk1 inhibitor and the use thereof
TW202012405A (en) 2018-07-24 2020-04-01 瑞士商赫孚孟拉羅股份公司 Naphthyridine compounds and uses thereof
JP7386841B2 (en) 2018-07-24 2023-11-27 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Isoquinoline compounds and their uses
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
CN113015526A (en) 2018-09-19 2021-06-22 豪夫迈·罗氏有限公司 Spirocyclic 2, 3-dihydro-7-azaindole compounds and uses thereof
WO2020069402A1 (en) 2018-09-30 2020-04-02 Genentech, Inc. Cinnoline compounds and for the treatment of hpk1-dependent disorders such as cancer
TW202024053A (en) 2018-10-02 2020-07-01 美商建南德克公司 Isoquinoline compounds and uses thereof
TW202023558A (en) 2018-10-03 2020-07-01 美商建南德克公司 8-aminoisoquinoline compounds and uses thereof
CN113227049A (en) 2018-10-05 2021-08-06 艾科诺斯科技股份有限公司 Indolinone compounds as MAP4K1 inhibitors
IL262658A (en) 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
MX2021005047A (en) 2018-10-31 2021-09-08 Gilead Sciences Inc Substituted 6-azabenzimidazole compounds as hpk1 inhibitors.
JP7273172B2 (en) * 2018-10-31 2023-05-12 ギリアード サイエンシーズ， インコーポレイテッド Substituted 6-azabenzimidazole compounds with HPK1 inhibitory activity
US11142525B2 (en) 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
WO2020103896A1 (en) 2018-11-22 2020-05-28 Beigene, Ltd. Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof
CN113423427A (en) 2018-11-30 2021-09-21 凯麦拉医疗公司 IRAK degrading agents and uses thereof
US20220047603A1 (en) 2018-12-11 2022-02-17 Bayer Aktiengesellschaft Substituted pyrrolopyridine-derivatives
JP2022519636A (en) 2019-02-04 2022-03-24 スカイホーク・セラピューティクス・インコーポレーテッド Methods and compositions for regulating splicing
CN114007611A (en) 2019-02-04 2022-02-01 斯基霍克疗法公司 Methods and compositions for modulating splicing
CN113645970A (en) 2019-02-05 2021-11-12 斯基霍克疗法公司 Methods and compositions for modulating splicing
EP3920918A4 (en) 2019-02-05 2022-11-16 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163405A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
KR20210135507A (en) 2019-02-06 2021-11-15 스카이호크 테라퓨틱스, 인코포레이티드 Methods and compositions for controlling splicing
US20220153766A1 (en) 2019-03-15 2022-05-19 Hangzhou Innogate Pharma Co., Ltd. Condensed tricyclic compound used as kinase inhibitor
CA3129772A1 (en) 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv Bicyclic hpk1 inhibitors
WO2020193511A1 (en) 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv Hpk1 inhibitors
JP2022526424A (en) 2019-04-09 2022-05-24 エンビサジェニックス， インコーポレイテッド Cancer-specific molecules and methods of their use
EA202192755A1 (en) 2019-04-24 2022-03-23 Стоук Терапьютикс, Инк. METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING AND BROADCASTING
CN114423463A (en) 2019-05-06 2022-04-29 西奈山伊坎医学院 Heterobifunctional compounds as HPK1 degradants
EP3971190A4 (en) 2019-05-17 2023-06-14 Voronoi Inc. Heterocycle-fused pyrimidine derivative and use thereof
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
WO2020255022A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors
CN114555585A (en) 2019-07-04 2022-05-27 上海齐鲁锐格医药研发有限公司 HPK1 inhibitors and uses thereof
TW202116773A (en) 2019-07-04 2021-05-01 英屬開曼群島商百濟神州有限公司 Pyrrolo[2,3-b]pyrazines as hpk1 inhibitor and the use thereof
TW202116753A (en) 2019-07-11 2021-05-01 大陸商南京征祥醫藥有限公司 Cinnolines as inhibitors of hpk 1
WO2021004547A1 (en) 2019-07-11 2021-01-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of hpk1
US20220267354A1 (en) 2019-07-17 2022-08-25 Beigene, Ltd. Tricyclic compounds as hpk1 inhibitor and the use thereof
EP4010338A1 (en) 2019-08-06 2022-06-15 Incyte Corporation Solid forms of an hpk1 inhibitor
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
CA3148011A1 (en) 2019-08-15 2021-02-18 Nicole M. Lykens Splice modulating oligonucleotides targeting receptor for advanced glycation end products and methods of use
US20220289712A1 (en) 2019-08-21 2022-09-15 Beigene, Ltd. Aminopyrazine compounds as hpk1 inhibitor and the use thereof
WO2021046254A1 (en) 2019-09-04 2021-03-11 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs for splice modulation
JP2022547719A (en) 2019-09-13 2022-11-15 ニンバス サターン， インコーポレイテッド HPK1 antagonists and uses thereof
CN112552293A (en) 2019-09-25 2021-03-26 珠海宇繁生物科技有限责任公司 PROTAC small molecular compound and application thereof
WO2021074279A1 (en) 2019-10-16 2021-04-22 Bayer Aktiengesellschaft Spiro-fused tricyclic map4k1 inhibitors
EP4090663A1 (en) 2020-01-15 2022-11-23 Blueprint Medicines Corporation Map4k1 inhibitors
CN113336747A (en) 2020-03-03 2021-09-03 轶诺(浙江)药业有限公司 Novel HPK1 inhibitor and preparation method and application thereof
WO2021213317A1 (en) 2020-04-20 2021-10-28 微境生物医药科技(上海)有限公司 Hpk1 inhibitor, preparation method therefor and use thereof
IL297838A (en) 2020-05-01 2023-01-01 Pfizer Azalactam compounds as hpk1 inhibitors
CN115605488A (en) 2020-05-06 2023-01-13 新锐思生物制药股份有限公司（Us） Bifunctional degradants of hematopoietic progenitor kinases and therapeutic uses thereof
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
WO2021226707A1 (en) 2020-05-11 2021-11-18 University Health Network Salt and crystal forms of 4-amino-5-(6-(4-methylpiperazin-1-yl)-1h-benzo[d]imidazol-2-yl)thieno[2,3-b]pyridin-6(7h)-one
WO2021249913A1 (en) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
KR20230026387A (en) 2020-06-16 2023-02-24 주하이 유판 바이오테크놀로지스 컴파니 리미티드 Use of HPK1 kinase inhibitors in the prevention and/or treatment of pathogen infections in animals
CN113845531A (en) 2020-06-28 2021-12-28 四川科伦博泰生物医药股份有限公司 Pyrazolo ring compound, pharmaceutical composition containing same, preparation method and application thereof
CN116731046A (en) 2020-10-28 2023-09-12 杭州阿诺生物医药科技有限公司 High-activity HPK1 kinase inhibitor
CN114437058A (en) 2020-10-30 2022-05-06 珠海宇繁生物科技有限责任公司 Deuterated HPK1 kinase inhibitor and preparation method and application thereof
CN114437074A (en) 2020-11-03 2022-05-06 北京伯汇生物技术有限公司 Compound, pharmaceutical composition containing compound and application of compound
US20230406864A1 (en) 2020-11-09 2023-12-21 Merck Sharp & Dohme Llc 7-azole substituted 2-aminoquinazoline inhibitors of hpk1
WO2022098809A1 (en) 2020-11-09 2022-05-12 Merck Sharp & Dohme Corp. Diaminopyrimidine carboxamide inhibitors of hpk1
EP4240363A1 (en) 2020-11-09 2023-09-13 Merck Sharp & Dohme LLC 7-phenyl substituted 2-aminoquinazoline inhibitors of hpk1
WO2022100688A1 (en) 2020-11-13 2022-05-19 南京红云生物科技有限公司 Hpk1 kinase modulator, preparation method therefor, and application thereof
WO2022107919A1 (en) 2020-11-19 2022-05-27 주식회사 보로노이 N-containing heteroaryl derivative, and pharmaceutical composition for preventing or treating protein kinase-related diseases comprising same as active ingredient
CN114516857A (en) 2020-11-20 2022-05-20 深圳智药信息科技有限公司 HPK1 inhibitors and uses thereof
JP2023550380A (en) 2020-11-24 2023-12-01 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Deuterium-modified thienopyridone compounds
WO2022131741A1 (en) 2020-12-14 2022-06-23 보로노이바이오 주식회사 Isoxazolidine derivative compound and use thereof
CN114685490A (en) 2020-12-31 2022-07-01 江苏先声药业有限公司 Pyrrolopyridine compound and application thereof
CN114685489A (en) 2020-12-31 2022-07-01 江苏先声药业有限公司 Polysubstituted nitrogen-containing heterocyclic compound and application thereof
CN114805330A (en) 2021-01-22 2022-07-29 苏州信诺维医药科技股份有限公司 HPK1 inhibitor, preparation method thereof, pharmaceutical composition and application thereof
EP4288437A1 (en) 2021-02-05 2023-12-13 Bayer Aktiengesellschaft Map4k1 inhibitors
CN114907375A (en) 2021-02-07 2022-08-16 苏州信诺维医药科技股份有限公司 Heterocyclic compound, preparation method thereof, pharmaceutical composition and application
CN114907374A (en) 2021-02-07 2022-08-16 苏州信诺维医药科技股份有限公司 Heterocyclic compound, preparation method thereof, pharmaceutical composition and application
WO2022166920A1 (en) 2021-02-08 2022-08-11 杭州中美华东制药有限公司 Pyrrolopyridazine compound, and preparation method therefor and use thereof
WO2022171034A1 (en) 2021-02-10 2022-08-18 江苏先声药业有限公司 Bicyclic compound as hpk1 inhibitor and application thereof
CN114907377A (en) 2021-02-10 2022-08-16 江苏恒瑞医药股份有限公司 Condensed tetracyclic compound, preparation method and medical application thereof
JP2024506909A (en) 2021-02-12 2024-02-15 ニンバス サターン， インコーポレイテッド HPK1 antagonists and their uses
CN116981661A (en) 2021-03-03 2023-10-31 劲方医药科技(上海)有限公司 Condensed ring substituted six-membered heterocyclic compound, preparation method and application thereof
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
EP4305041A1 (en) 2021-03-08 2024-01-17 Blueprint Medicines Corporation Map4k1 inhibitors
WO2022188735A1 (en) 2021-03-08 2022-09-15 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as hpk1 inhibitors
CN116888127A (en) 2021-03-10 2023-10-13 轩竹生物科技股份有限公司 Tri-fused ring HPK1 inhibitor and application thereof
US11918582B2 (en) 2021-03-15 2024-03-05 Rapt Therapeutics, Inc. Pyrazole pyrimidine compounds and uses thereof
CN113861188B (en) 2021-08-23 2023-02-28 杭州医学院 Pyrazolo [3,4-b ] pyridine derivative, preparation method thereof and application thereof as HPK1 inhibitor
CN114315796B (en) 2021-12-30 2024-03-26 中国药科大学 Compounds used as HPK1 kinase inhibitor, preparation method and application thereof
CN114767676B (en) 2022-04-22 2024-04-19 珠海宇繁生物科技有限责任公司 Use of HPK1 kinase inhibitors for the prevention and/or treatment of pathogen infection in humans
CN114853730B (en) 2022-05-27 2024-03-26 中国药科大学 Compounds used as HPK1 kinase inhibitor, preparation method and application thereof
CN114940683B (en) 2022-07-26 2023-01-17 轩竹(北京)医药科技有限公司 HPK1 inhibitors and uses thereof

Also Published As

Publication number Publication date
CN113227089A (en) 2021-08-06
AU2019372046B2 (en) 2022-05-26
US20210115037A1 (en) 2021-04-22
PE20211655A1 (en) 2021-08-24
TW202033522A (en) 2020-09-16
CA3117556A1 (en) 2020-05-07
AU2024203579A1 (en) 2024-06-20
EP3873903B1 (en) 2024-01-24
MX2021005047A (en) 2021-09-08
WO2020092621A1 (en) 2020-05-07
US20220213091A1 (en) 2022-07-07
IL282535A (en) 2021-06-30
PH12021551019A1 (en) 2022-02-21
JP2022509533A (en) 2022-01-20
TW202136260A (en) 2021-10-01
IL282535B1 (en) 2024-01-01
CO2021005711A2 (en) 2021-05-20
US11203591B2 (en) 2021-12-21
PT3873903T (en) 2024-05-16
KR102650496B1 (en) 2024-03-26
IL282535B2 (en) 2024-05-01
PL3873903T3 (en) 2024-05-20
LT3873903T (en) 2024-05-10
AU2022218506B2 (en) 2024-06-13
JP2024026363A (en) 2024-02-28
TWI721623B (en) 2021-03-11
FI3873903T3 (en) 2024-03-26
EP3873903A1 (en) 2021-09-08
DK3873903T3 (en) 2024-04-02
CL2021001132A1 (en) 2021-11-26
BR112021008255A2 (en) 2021-08-03
JP7460644B2 (en) 2024-04-02
US11897878B2 (en) 2024-02-13
DOP2021000079A (en) 2021-06-15
DOP2023000252A (en) 2024-02-15
KR20210086685A (en) 2021-07-08
AU2022218506A1 (en) 2022-09-08
CR20210215A (en) 2021-06-17
EP4371987A1 (en) 2024-05-22
UA126619C2 (en) 2022-11-02
AU2019372046A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
IL282535A (en) Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
HUS2400003I1 (en) Compounds useful as kinase inhibitors
GB201705971D0 (en) Inhibitor compounds
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
ZA201708244B (en) Thioether compounds as nitrification inhibitors
GB201819126D0 (en) Inhibitor compounds
RS63203B1 (en) Compounds useful as ripk1 inhibitors
GB201505658D0 (en) Inhibitor compounds
IL290087A (en) Inhibitor compounds
GB201914860D0 (en) Inhibitor compounds
GB201507036D0 (en) Crystalline enzyme inhibitor compound
GB201905328D0 (en) Inhibitor compounds
GB201819136D0 (en) Inhibitor compounds
GB201806131D0 (en) Inhibitor compounds
GB201806130D0 (en) Inhibitor compounds
GB201905318D0 (en) Inhibitor compounds
GB201720145D0 (en) Inhibitor compounds
GB201708510D0 (en) Inhibitor compounds
GB201708507D0 (en) Inhibitor compounds
GB201708502D0 (en) Inhibitor compounds
GB201705968D0 (en) Inhibitor compounds
GB201621619D0 (en) Inhibitor compounds
GB201613945D0 (en) Compounds useful as kinase inhibitors
GB201522245D0 (en) Compounds useful as kinase inhibitors
GB201500644D0 (en) Inhibitor compounds